financetom
Business
financetom
/
Business
/
Form 8.3
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Form 8.3
Nov 12, 2025 10:44 AM

LONDON--(BUSINESS WIRE)--

 

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Full name of discloser:

Oberweis Asset Management, Inc.

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

N/A

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Greencore Group Plc ( GNCGF )

If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

N/A

(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

12/11/2025

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state “N/A”

No

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:

 

1 p ordinary share

 

 

Interests

Short positions

 

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

5,005,300

1.13%

 

 

(2) Cash-settled derivatives:

 

 

 

 

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

 

 

 

 

TOTAL:

5,005,300

1.13%

 

 

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:

 

Details, including nature of the rights concerned and relevant percentages:

 

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit

1 p ordinary share

Sale

17,900

£2.30

(b) Cash-settled derivative transactions

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

 

 

 

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

 

 

 

 

 

 

 

(ii) Exercise

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

 

 

 

(d) Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

 

 

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

 

None

 

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state “none”

 

 

None

(c) Attachments

Class of relevant security:

 

1 p ordinary share

 

 

Interests

Short positions

 

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

5,005,300

1.13%

 

 

(2) Cash-settled derivatives:

 

 

 

 

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

 

 

 

 

TOTAL:

5,005,300

1.13%

 

 

0

Class of relevant security:

 

1 p ordinary share

 

 

Interests

Short positions

 

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

5,005,300

1.13%

 

 

(2) Cash-settled derivatives:

 

 

 

 

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

 

 

 

 

TOTAL:

5,005,300

1.13%

 

 

1

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel’s Market Surveillance Unit.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

Source: Oberweis Asset Management, Inc.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BP Scores Major Win Against Venture Global In LNG Dispute
BP Scores Major Win Against Venture Global In LNG Dispute
Oct 10, 2025
Venture Global, Inc. ( VG ) shares are tumbling premarket on Friday after a wholly-owned subsidiary of BP p.l.c ( BP ). won an arbitration against the company over its failure to supply liquefied natural gas. BP Wins Arbitration Against Venture Global This week, the International Chamber of Commerce (ICC) issued a partial final award in the arbitration with BP...
Bitfarms Converts Debt Facility Into $300 Million Funding for Pennsylvania Data Center Campus
Bitfarms Converts Debt Facility Into $300 Million Funding for Pennsylvania Data Center Campus
Oct 10, 2025
10:10 AM EDT, 10/10/2025 (MT Newswires) -- Bitfarms ( BITF ) said Friday that it has converted its existing private debt facility for up to $300 million from Macquarie Group's Commodities and Global Markets business into a project-specific financing facility for its data center campus in Panther Creek, Pennsylvania. The company said it will draw an additional $50 million from...
Next medicine deal after Pfizer? Analysts, shares point to AstraZeneca, Eli Lilly
Next medicine deal after Pfizer? Analysts, shares point to AstraZeneca, Eli Lilly
Oct 10, 2025
By Bhanvi Satija and Maggie Fick LONDON, Oct 10 (Reuters) - Wall Street is looking to U.S. drugmaker Eli Lilly ( LLY ) and Anglo-Swedish rival AstraZeneca ( AZN ) as the potential next in line after Pfizer ( PFE ) struck a deal with Donald Trump's administration to lower drug prices last week. Reuters spoke to seven healthcare analysts...
Quoin Pharmaceuticals Shares Jump After Announcing $104.5 Million Private Placement
Quoin Pharmaceuticals Shares Jump After Announcing $104.5 Million Private Placement
Oct 10, 2025
10:12 AM EDT, 10/10/2025 (MT Newswires) -- Quoin Pharmaceuticals ( QNRX ) shares jumped nearly 170% in recent Friday trading after the company said it has reached an agreement with healthcare-focused institutional investors to sell securities worth up to $104.5 million in a private placement. The drugmaker said it will sell about 2 million American depositary shares or pre-funded warrants...
Copyright 2023-2026 - www.financetom.com All Rights Reserved